Luciana Molinero
Luciana Molinero is an expert in Oncology at Genentech Inc. (United States). Luciana Molinero has authored 128 publications, the most recent in 2025, and is an investigator in 7 clinical trials. SLR score: 743 (community average: 125). How the SLR is computed.
LeadR Profile
Oncology
Subspecialties: Gynecology - Public Health - Biochemistry
Main Topics
Publications and Clinical Studies
Profile data updated on
Expert Rankings
Top experts on the MeSH terms this expert works on
Organizations
Career arc: 2002 - 2025
Number : 128
Citations
Main journals
Best Journals
Breakdown by type
Click a legend label to hide or show it in the chart.
Latest Publications
5 most recent indexed articles
Source: Pubmed
| Title | Journal | Year | Citations |
|---|---|---|---|
| Digital Versus Manual PD-L1 Scoring in Advanced Non-Small Cell Lung Cancer From the IMpower110 and IMpower150 Trials. PMID 40759194 — cells, telepathology, lung, paclitaxel, neoplasms, carcinoma, non-small-cell lung, bevacizumab, lung neoplasms, small cell lung carcinoma, therapeutics, artificial intelligence, carboplatin | J Thorac Oncol | 2025 | 0 |
| Peri-operative atezolizumab in early-stage triple-negative breast cancer: final results and ctDNA analyses from the randomized phase 3 IMpassion031 trial. PMID 40467898 — triple negative breast neoplasms, disease-free survival, breast neoplasms, molecular biology, neoplasms, drug therapy, breast, therapeutics, chemotherapy | Nat Med Top journal | 2025 | 0 |
| Adjuvant Atezolizumab for Early Triple-Negative Breast Cancer: The ALEXANDRA/IMpassion030 Randomized Clinical Trial. PMID 39883436 — triple negative breast neoplasms, disease-free survival, breast neoplasms, incidence, pharmaceutical preparations, neoplasms, drug therapy, drug-related side effects and adverse reactions, breast, therapeutics, chemotherapy | JAMA Top journal | 2025 | 27 |
| PARP inhibition with rucaparib alone followed by combination with atezolizumab: Phase Ib COUPLET clinical study in advanced gynaecological and triple-negative breast cancers. PMID 38971950 — cells, triple negative breast neoplasms, breast neoplasms, neoplasms, breast, therapeutics, t-lymphocytes | Br J Cancer | 2024 | 9 |
| A non-comparative, randomized, phase II trial of atezolizumab or atezolizumab plus tiragolumab for programmed death-ligand 1-positive recurrent cervical cancer (SKYSCRAPER-04). PMID 38858106 — ligands, drug-related side effects and adverse reactions, therapeutics, uterine cervical neoplasms, disease-free survival, genital neoplasms, female, b7-h1 antigen, progression-free survival | Int J Gynecol Cancer | 2024 | 1 |
Clinical Studies 7
Synthesis
By phase:
By status:
By type:
By Monocentric/Multicentric:
LeadR Networks
Main global connection map